Intriguingly, in a murine model bearing heavy tumor burden, treatment with Allo15CAR33-NKT cells demonstrated a distinct advantage over CAR33-T cells, manifesting in less changes of body weight and reduced levels of CRS-associated biomarkers, such as mouse IL-6 and serum amyloid A-3 (SAA-3), in both mouse serum and peritoneal fluid (Fig. 9i–l). Here, IL6 is linked to neoplasm.